Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial.

Current medicinal chemistry
Q1
Mar 2013
Citations:167
Influential Citations:6
Interventional (Human) Studies
84
S2 IconPDF Icon

Enhanced Details

Methods
Randomized, double-blind, placebo-controlled cross-over trial. 50 healthy adult smokers aged 20-50 years (current smoking ≥5 cigarettes/day and >20 packs/year).
Intervention
Resveratrol 500 mg daily (one tablet in the morning after overnight fasting) for 30 days; 30-day washout; then placebo for 30 days. In the alternate sequence, placebo for 30 days, washout, then resveratrol 500 mg daily for 30 days.
Results
Resveratrol significantly reduced C-reactive protein (CRP) and triglyceride concentrations and increased total antioxidant status (TAS), indicating anti-inflammatory and antioxidant effects in healthy smokers. No significant changes were observed in weight, waist circumference, blood pressure, or other metabolic variables. These findings suggest potential health benefits of resveratrol in smokers, but longer-term trials are needed to confirm clinical relevance and safety before recommendations for disease prevention or treatment.
Limitations
Short follow-up period and small sample size (n=50; 49 analyzed); compliance not measured (plasma resveratrol not assessed); potential carry-over effects inherent to cross-over design; results limited to healthy smokers with baseline values in the reference range; long-term safety and optimal dosing remain undetermined.

Abstract

OBJECTIVE Smokers are characterized by a low-grade systemic inflammatory state and an oxidant-antioxidant imbalance. Few human studies were conducted on the effects of resveratrol, a natural compound with anti-inflammatory and antioxidant properties,...